GLP-1tirzepatideatrial fibrillationstroketype 2 diabetes

Tirzepatide linked to lower stroke risk than other GLP-1 agonists in atrial fibrillation

Retrospective federated health-record analysis of 14,118 matched pairs also found a 6.2 percentage point absolute difference in all-cause mortality at one year.

By Maren Holt · Senior Reporter, GLP-1

Aug 21 20:00 ETSource: Nature communications

The wire

01In Nature Communications, researchers matched 14,118 pairs of adults with atrial fibrillation and type 2 diabetes starting tirzepatide or another GLP-1 receptor agonist; stroke risk differed by 2.1 percentage points at one year.
02Lower risks were reported for any stroke, ischemic stroke, hemorrhagic stroke and death, a signal clinicians may weigh when selecting incretin therapy for anticoagulated patients with diabetes.
03The authors state the findings are observational and that randomized trials are required before treatment recommendations change; residual confounding in electronic health-record cohorts remains a limitation.

From the source

Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes
Nature communications · 2026 Aug 22 · Lin CL, Lin KC, Yu JM et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42778559/